Answer
Serious hepatic toxicity consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, has occurred in patients treated with polatuzumab vedotin (Polivy).
Sources for this answer
- Polivy 30 mg and 140 mg powder for concentrate for solution for infusionRoche Products Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 8Document updated
Sources checked